# CJC-1295 Ipamorelin: Frequently Asked Questions > CJC-1295 ipamorelin frequently asked questions — mechanism, dosage, half-life, side effects, regulatory status, reconstitution, timing, and comparison with sermorelin and MK-677. Cited answers. ## Definitions and Overview ### What are CJC-1295 and ipamorelin? CJC-1295 is a synthetic GHRH analog studied for sustained GH release via albumin-bound half-life extension. Ipamorelin is a selective GHRP that binds GHS-R1a for pulsatile GH secretion with minimal cortisol, prolactin, or gonadotropin side effects in published rat and swine studies.[3] Combined, they operate on two distinct receptor arms of the GH axis. ### What is CJC-1295 ipamorelin good for? Studied in preclinical models for GH pulsatility and IGF-1 elevation,[1] bone mineral content and longitudinal growth,[4][9] periosteal bone formation rate under glucocorticoid stress,[8] gastrointestinal motility restoration via GHS-R1a agonism,[10] and sleep architecture via ghrelin-receptor mechanisms.[12] No FDA-approved indication exists for either compound. ### Why are CJC-1295 and ipamorelin used together? CJC-1295 amplifies the GH baseline through GHRH receptor agonism while ipamorelin triggers acute GH pulses via ghrelin-receptor binding. The two axes act supraadditively: a near-threshold GHS dose plus a maximally effective GHRH dose produced greater-than-additive GH release across five species.[13] ### Is CJC-1295 an HGH-releasing hormone? CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — it mimics endogenous GHRH by binding pituitary GHRH receptors to amplify GH secretion. It does not administer GH directly. In human studies at 60–90 µg/kg SC, mean GH rose 46% and IGF-1 rose 45% at one week.[1] ## Pharmacokinetics and Timing ### What is the half-life of CJC-1295 and ipamorelin? CJC-1295 without DAC: below 30 minutes (DPP-IV-limited).[16] CJC-1295 with DAC: approximately 6–8 days (albumin-bound).[2] Ipamorelin: approximately 2 hours in rodents — no validated human half-life data published.[7] ### What is the difference between CJC-1295 with DAC and without DAC? DAC modification extends CJC-1295 half-life to approximately 6–8 days by forming a covalent in vivo bond with serum albumin. Without DAC, CJC-1295 retains amino acid substitutions resisting DPP-IV but lacks albumin binding. The DAC form produced a 4-fold increase in GH AUC over 2 hours compared with native hGRF(1-29).[2] ### Should CJC-1295/ipamorelin be taken fasted or with food? Research protocols typically specify fasted administration. In a 5-day fasting study in men, GH pulse frequency increased from 5.8 to 9.9 pulses per 24 hours and 24-hour GH concentration nearly tripled (p=0.0002), with reduced insulin establishing somatostatin suppression as the mechanism.[11] ### How often should you inject CJC ipamorelin? Published CJC-1295 with DAC protocols: once-weekly or less frequent SC injection.[1] Ipamorelin in animal models: 1–3 daily pulses.[4][8][10] Human combination frequency protocols not published. ## Safety and Side Effects ### What are the side effects of CJC-1295 and ipamorelin? CJC-1295 clinical study participants: injection-site reactions, transient facial flushing, peripheral edema, mild headache. No serious adverse events in published healthy-subject Phase I/II-context trials. Ipamorelin Phase I data confirmed no cortisol, ACTH, FSH, LH, or prolactin elevation even at 200-fold above GH ED50.[3] ### Does CJC-1295 raise testosterone? CJC-1295 published clinical trials did not report significant changes in testosterone, LH, or FSH. Ipamorelin's selectivity data confirmed no FSH or LH elevation at 200-fold above GH ED50.[3] ### Does CJC-1295/ipamorelin cause cancer? No published trial in healthy subjects attributed tumor development to CJC-1295 or ipamorelin. IGF-1 elevation is a theoretical oncologic concern; published CJC-1295 human trials reported no tumor-related events.[1][6] The theoretical concern has not been resolved in controlled long-term human data. ## Efficacy and Outcomes ### Does CJC-1295 ipamorelin work? CJC-1295 Phase II trials demonstrated statistically significant mean GH and IGF-1 increases versus baseline.[1] GHS synergy confirmed across five species.[13] Combination human efficacy data in controlled trials do not exist in peer-reviewed literature. ### How long does it take to see results from CJC-1295 and ipamorelin? CJC-1295 Phase II trials: IGF-1 elevation within 2 weeks; sustained up to 28 days post-dose (DAC form).[1] Bone and body composition endpoints in animal studies: measurable changes at 4–8 weeks.[4][8][9] ## Comparisons ### CJC-1295 ipamorelin vs sermorelin: what are the differences? Sermorelin is GRF(1-29) without DPP-IV-resistant substitutions or DAC albumin-binding; half-life below 30 minutes. CJC-1295 DAC: approximately 6–8-day half-life.[16][2] No published head-to-head human comparison exists. ### Which is better: MK-677 or CJC-1295 ipamorelin? MK-677 is an oral ghrelin mimetic with a 24-hour half-life and continuous GH/IGF-1 elevation. CJC-1295/ipamorelin produces pulsatile GH release preserving circadian rhythm. MK-677 (25 mg/day) elevated mean 24-hour GH 97% ± 23% in 32 elderly subjects.[14] No direct comparison studies exist. ## Regulatory and Practical ### Is CJC-1295/ipamorelin FDA-approved? Neither CJC-1295 nor ipamorelin holds FDA approval for any human indication. As of December 2024 FDA PCAC briefing documents, CJC-1295 acetate forms were proposed not to be included on the 503A Bulks List. Neither compound has completed Phase III trials. ### Can CJC-1295/ipamorelin be used alongside testosterone replacement therapy? No published controlled trial has formally studied this combination. A published study of GHRP-6 + GHRP-2 + sermorelin in hypogonadal men on TRT showed IGF-1 elevation without serious adverse events.[15] ## References [1] Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/ [2] Jetté L, et al. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/ [3] Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/ [4] Johansen PB, et al. Growth Horm IGF Res. 1999;9(2):106-113. https://pubmed.ncbi.nlm.nih.gov/10373343/ [6] Sackmann-Sala L, et al. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/ [7] Johansen PB, et al. Xenobiotica. 1998;28(12):1243-1252. https://pubmed.ncbi.nlm.nih.gov/9879640/ [8] Andersen NB, et al. Growth Horm IGF Res. 2001;11(5):266-272. https://pubmed.ncbi.nlm.nih.gov/11735244/ [9] Svensson J, et al. J Endocrinol. 2000;165(3):569-577. https://pubmed.ncbi.nlm.nih.gov/10828840/ [10] Venkova K, et al. J Pharmacol Exp Ther. 2009;329(3):1110-1116. https://pubmed.ncbi.nlm.nih.gov/19289567/ [11] Ho KY, et al. J Clin Invest. 1988;81(4):968-975. https://pubmed.ncbi.nlm.nih.gov/3127426/ [12] Weikel JC, et al. Am J Physiol Endocrinol Metab. 2003;284(2):E407-E415. https://pubmed.ncbi.nlm.nih.gov/12388174/ [13] Farhy LS, Veldhuis JD. Am J Physiol Regul Integr Comp Physiol. 2005;288(5):R1649-R1663. https://pubmed.ncbi.nlm.nih.gov/15718392/ [14] Chapman IM, et al. J Clin Endocrinol Metab. 1996;81(12):4249-4257. https://pubmed.ncbi.nlm.nih.gov/8954023/ [15] Sigalos JT, et al. Am J Mens Health. 2017;11(6):1752-1757. https://pubmed.ncbi.nlm.nih.gov/28830317/ [16] Memdouh S, et al. Drug Test Anal. 2021;13(7):1233-1247. https://pubmed.ncbi.nlm.nih.gov/34665524/ --- Twenty-two studies across six species, indexed as a folk-almanac of the CJC-1295 ipamorelin literature — no clinic behind the cordel, no vendor behind the broadside.